Variation on a theme: CMR as the "one-stop shop" for risk stratification after infarction?
Wu
Katherine C
KC
D000318:Adrenergic beta-Agonists; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000401:mortality; D003331:Coronary Vessels / Q000473:pathology; D004280:Dobutamine; D006333:Heart Failure / Q000209:etiology / Q000401:mortality; D006801:Humans; D019028:Magnetic Resonance Imaging, Cine; D055806:Microvessels / Q000473:pathology; D009200:Myocardial Contraction; D009203:Myocardial Infarction / Q000150:complications / Q000175:diagnosis* / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D009206:Myocardium / Q000473:pathology*; D009336:Necrosis; D011237:Predictive Value of Tests; D011379:Prognosis; D012008:Recurrence; D018570:Risk Assessment; D012307:Risk Factors; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000401:mortality; D013997:Time Factors; D016896:Treatment Outcome
D000318:Adrenergic beta-Agonists; D004280:Dobutamine